Market Newsdesk

SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ — Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts. The lawsuit seeks to represent investors who purchased or otherwise acquired PROCEPT common stock between February 28, 2024 and February 25, 2026.

National shareholders rights firm Hagens Berman is investigating legal claims that PROCEPT and the other Defendants violated the federal securities laws in their communications about sales of the company’s single-use handpiece, a component of its proprietary Aquablation therapy used to treat patients with an enlarged prostate.

The firm encourages investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm’s attorneys.

Class Period: Feb. 28, 2024 – Feb. 25, 2026
Lead Plaintiff Deadline: Sept. 22, 2026
Visit: www.hbsslaw.com/investor-fraud/prct
Contact the Firm Now: [email protected]
                                        844-916-0895

PROCEPT BioRobotics (PRCT) Securities Class Action:

The lawsuit alleges that during the Class Period, the defendants withheld crucial information from investors about PROCEPT’s business, operations, and financial condition. Its focus is on the propriety of the company’s statements and omissions related to handpiece sales practices in the U.S., including repeated touting of growth in those sales.

More specifically, the complaint alleges that (unknown to investors) the wrongdoing consisted of company’s utilization of an extensive discount program to incentivize its customers to place bulk orders exceeding customers’ procedures demands, pulling forward sales at the expense of future periods and, thereby, artificially inflating reported unit sales and revenues.

Investors began to learn the truth through a series of partial disclosures, each of which drove the price of PROCEPT shares sharply lower.

On August 6, 2025, PROCEPT announced its Q2 2025 financial results, revealing that the company’s handpiece sales unexpectedly deteriorated, missing consensus estimates by a wide margin.

Then, on November 4, 2025 PROCEPT reported its Q3 2025 results, again missing expected handpiece unit sales. During the corresponding earnings call, management slashed annual handpiece unit sales guidance to allow for the “optimization of field inventory[,]” and said PROCEPT had not “been managing customer inventory[,]” adding that some customers were “probably carrying too much.”

Finally, on February 25, 2026 PROCEPT announced Q4 2025 results. For the first time, the company disclosed the actual number of procedures in the field and revealed that U.S. handpiece sales materially exceeded procedures in each quarter since Q1 2023.

Of concern was that cumulative excess customer inventory of handpieces were over 10,000 units and U.S. handpiece sales sequentially cratered by 30%. Management then said that the company was eliminating its (previously undisclosed) bulk order discount program which was designed to incentivize customers to make large purchases during “the final weeks” of every quarter. The problem was the bulk order discount program essentially ate into future sales as customers already had excess inventories. 

As a result of these events, by February 25, the price of PROCEPT shares had steadily declined by $22.06, or over 48% from the close on August 6, 2025.

“We’re focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in PROCEPT and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the PROCEPT case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding PROCEPT should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/prct-investor-alert-procept-biorobotics-corporation-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302853588.html

SOURCE Hagens Berman Sobol Shapiro LLP

BFA Law has filed a securities fraud class action lawsuit on behalf of Hub Group investors after its stock plummeted 18% after it announced its financial statements were materially misstated and should no longer be relied upon.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Hub Group Inc. (NASDAQ:HUBG) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Hub Group, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit.

Key Details of the HUBG ($HUBG) Class Action:

• Lead Plaintiff Deadline: August 28, 2026
• 
  Alleged Misconduct: Securities fraud relating to Hub Group’s financial results, revenue recognition, accounting of costs, internal controls, and prospects for/drivers of growth
• Largest Stock Drop: February 6, 2026 – 18% Stock Drop
• Court: U.S. District Court for the Northern District of Illinois
• Filing Law Firm: Bleichmar Fonti & Auld (“BFA Law”)
• Action: Contact BFA Law to discuss your rights

Investors have until August 28, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Hub Group securities. The class action is pending in the U.S. District Court for the Northern District of Illinois. It is captioned Lawler v. Hub Group, Inc., No. 1:26-cv-07596.

Why is Hub Group Being Sued for Securities Fraud?

Hub Group is a transportation and logistics freight carrier that provides trucking and related services to operators across the supply chain. Hub Group services a customer base extending across various industries, including retail, consumer products, automotive, and durable goods, and reports to be one of the largest freight transportation providers in North America. 

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements concerning the premature and incorrect revenue recognition of certain transactions, the understatement of purchased transportation costs and accounts payable, the effectiveness of internal controls, and the Hub Group’s drivers of financial results and growth.

Why did Hub Group’s Stock Drop?

On February 5, 2026, Hub Group announced that the Company’s financial statements for the first three quarters of 2025 should not be relied upon and would be restated due to “an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025.” Hub Group revealed that its reports for those quarters “were in each case materially misstated due to the aforementioned error and should no longer be relied upon” and that “the Company [wa]s also continuing to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting and appropriate remediation steps.”  Hub Group also estimated that “[t]he total amount of the reduction to accounts payable and purchased transportation costs related to this issue that was recorded during these periods is $77 million.”  

This news caused the price of Hub Group stock to decline roughly 18%, from $51.33 per share at close on February 5, 2026, to $41.96 per share at close on February 6, 2026.

On May 12, 2026, Hub Group announced that it had “identified certain transactions that were prematurely or incorrectly recognized or not adequately supported,” causing its 2023 and 2024 annual reports filed with the SEC to be “materially misstated,” such that they “should no longer be relied upon.”  Hub Group did not quantify the expected misstatement, although it “expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023.”

This news caused the price of Hub Group stock to decline a further 13%, from $41.86 per share at close on May 11, 2026, to $36.62 per share at close on May 12, 2026.

Click here for more information: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit.

What Can You Do?

If you invested in Hub Group, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/hub-group-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”  

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/hub-group-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hubg-stock-news-hub-group-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-18-stock-drop-302853488.html

SOURCE Bleichmar Fonti & Auld LLP

BFA Law is investigating whether Coastal Financial Corporation committed securities fraud relating to statements concerning the financial performance and credit quality of its banking as a service segment, including the company’s CCBX partner relationships.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Coastal Financial Corp. (NASDAQ: CCB) for potential securities fraud after its significant stock drop.

If you invested in Coastal Financial securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/coastal-financial-class-action-lawsuit.

Key Details of the Coastal Financial ($CCB) Class Action Investigation:

• Investigation Overview: Securities fraud investigation relating to the company’s statements concerning the credit quality and financial condition of Coastal Financial’s CCBX partner relationships and banking as a service segment
• Stock Decline: July 30, 2026 – 43.5% Stock Drop
• Action: Contact BFA Law to discuss your rights

Why is Coastal Financial Being Investigated for Securities Fraud?

Coastal Financial is a bank holding company based in Everett, Washington. The company provides banking as a service to digital financial service providers, companies, and brands that want to provide financial services to their customers through the bank’s CCBX segment.

BFA is investigating whether Coastal Financial misled investors about the financial performance and credit quality of its banking as a service segment, including the company’s CCBX partner relationships.

Why did Coastal Financial’s Stock Drop? 

On July 30, 2026, Coastal Financial reported its Q2 2026 financial results. The company revealed a quarterly net loss of $42.1 million, or $(2.76) per diluted common share, compared to net income of $12 million, or $0.78 per diluted common share, the prior year. Coastal Financial stated that its net loss was driven by a $68.8 million credit expense related to an unnamed CCBX partner relationship.

This news caused the price of Coastal Financial stock to decline $30.75 per share, or 43.5%, from a closing price of $70.66 per share on July 29, 2026, to $39.91 per share on July 30, 2026.

Click here for more information:

https://www.bfalaw.com/cases/coastal-financial-class-action-lawsuit

.

What Can You Do?

If you invested in Coastal Financial securities, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/coastal-financial-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/coastal-financial-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ccb-stock-news-coastal-financial-investigated-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-43-stock-drop-302853496.html

SOURCE Bleichmar Fonti & Auld LLP

A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.

Key Details of the Embecta ($EMBC) Class Action:

• Lead Plaintiff Deadline: August 17, 2026
• 
  Alleged Misconduct: Securities fraud relating to Embecta’s statements about the strength of its insulin pen needle product category.
• Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock Drop
• Court: U.S. District Court for the District of New Jersey
• Action: Contact BFA Law to discuss your rights

Investors have until August 17, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Apitz-Grossman v. Embecta Corp., et al., No. 26-cv-07217.

Why is Embecta Being Sued for Securities Fraud?

Embecta is a medical device company that produces insulin pens for patients with diabetes. According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that “prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio.”

As alleged, in truth, Embecta faced significant competition and “overall market softness for insulin pens and pen needles.”

Why did Embecta’s Stock Drop?

On May 5, 2026, Embecta announced disappointing Q2 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer. Embecta also reported an “overall market volume softness for insulin pens and pen needles in the retail channel,” admitting that “we have now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that we reported.” As a result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per share.

This news caused the price of Embecta common stock to decline $5.35 per share, or 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. 

Click here for more information:

https://www.bfalaw.com/cases/embecta-class-action-lawsuit

.

What Can You Do?

If you invested in Embecta, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/embecta-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/embecta-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/embc-stock-news-embecta-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-57-stock-drop-302853485.html

SOURCE Bleichmar Fonti & Auld LLP

A securities fraud class action lawsuit has been filed on behalf of ZoomInfo investors after its stock plummeted nearly 33% because ZoomInfo allegedly misled investors regarding its customer retention.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ZoomInfo Technologies Inc. (NASDAQ:GTM) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in ZoomInfo, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/zoominfo-class-action-lawsuit.

Key Details of the ZoomInfo ($GTM) Class Action:

• Lead Plaintiff Deadline: August 24, 2026

• 
  Alleged Misconduct: Securities fraud alleging that ZoomInfo misled investors regarding the impact of ZoomInfo’s AI-integrated products on customer retention

• Stock Drop: May 12, 2026 – 33% Stock Drop
• Court: U.S. District Court for the Western District of Washington
• Action: Contact BFA Law to discuss your rights

Investors have until August 24, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ZoomInfo securities. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Tejeda v. ZoomInfo Technologies et al., No. 26-cv-05696. 

Why is ZoomInfo Being Sued for Securities Fraud?

ZoomInfo has been sued for securities fraud following a significant stock drop resulting from potential violations of the federal securities laws.  The decline in ZoomInfo’s stock price caused significant losses to investors.

ZoomInfo provides go-to-market (“GTM”) intelligence and a customer engagement platform for sales, marketing, operations, and recruiting professionals. 

Throughout the relevant period, ZoomInfo allegedly stated that “the demand for AI for GTM is evident up and down our customer stack.”  According to ZoomInfo, its “innovative go-to-market AI” was “driving stronger daily engagement from a diverse set of go-to-market personas.” 

On February 9, 2026, ZoomInfo issued its 2026 revenue guidance “in the range of $1.247 billion to $1.267 billion,” because “in 2026, our focus is on bringing” ZoomInfo’s “all-in-one AI platform for go-to-market teams . . . to our customers at scale.” 

As alleged, ZoomInfo’s customer retention declined as customers were rejecting ZoomInfo’s AI products.

Why did ZoomInfo’s Stock Drop?

On May 11, 2026, ZoomInfo announced its Q1 2026 results and slashed its 2026 revenue guidance from $1.247-$1.267 billion to $1.185-$1.205 billion.  ZoomInfo revealed that its customer growth “regressed” due to “AI and agentic confusion” leading to “a pause in [customers’] purchasing decisions[.]”

This news caused the price of ZoomInfo stock to decline $1.98 per share, or 32.78%, from a closing price of $6.04 per share on May 11, 2026, to $4.06 per share on May 12, 2026.

Click here for more information: https://www.bfalaw.com/cases/zoominfo-class-action-lawsuit.

What Can You Do?

If you invested in ZoomInfo, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/zoominfo-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/zoominfo-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gtm-stock-news-zoominfo-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-33-stock-drop-302853492.html

SOURCE Bleichmar Fonti & Auld LLP

UWM has been sued for securities fraud after its stock plummeted 34.78% because UWM allegedly misrepresented its mortgage servicing rights hedging strategy and the risks created by hedging connected to the Two Harbors transaction.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against UWM Holdings Corporation (NYSE:UWMC) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in UWM, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit.

Key Details of the UWM ($UWMC) Class Action:

• Lead Plaintiff Deadline: October 13, 2026
• 
  Alleged Misconduct: Securities fraud alleging that UWM misrepresented its mortgage servicing rights hedging strategy and the risks created by hedging connected to the Two Harbors transaction 
• Stock Drop: August 6, 2026 – 34.78% Stock Drop
• Court: U.S. District Court for the Eastern District of Michigan
• Action: Contact BFA Law to discuss your rights

Investors have until October 13, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in UWM securities. The class action is pending in the U.S. District Court for the Eastern District of Michigan. It is captioned Bond v. UWM Holdings Corporation et al., No. 26-cv-12862.

Why is UWM Being Sued for Securities Fraud?

UWM originates, sells, and services residential mortgage loans in the United States. In December 2025, UWM and Two Harbors Investment Corp., owner of RoundPoint Mortgage Servicing, signed an all-stock merger agreement valued at $1.3 billion.

According to the complaint, in March 2026, Two Harbors terminated the UWM agreement after CrossCountry Mortgage made a competing cash offer and agreed to pay UWM’s termination fee.

As alleged, UWM failed to disclose that it had deviated from its traditional strategy of not hedging its mortgage servicing rights by taking a major hedge position, that it over-hedged itself in anticipation of the Two Harbors transaction, and that its purported efforts to balance risk created excess hedging risk.

Why did UWM’s Stock Drop?

On August 5, 2026, after the market closed, UWM reported Q2 2026 financial results, including a $603.2 million interest rate derivatives loss which contributed to a $451.9 million second-quarter net loss. Total equity also fell 43.6% year over year, reflecting the net loss and derivative-related charges.

Then, on August 6, 2026, UWM disclosed that it “over-hedged” while protecting against the Two Harbors transaction and stated that UWM does not traditionally hedge its mortgage servicing rights. UWM further disclosed that when it was acquiring Two Harbors and a large mortgage servicing rights book, “it created a little more risk,” that UWM “did put a hedge on to protect against that risk,” and that “the Two Harbors transaction went away,” creating a hedge loss. On this news, UWM’s stock dropped $0.64 per share, or 34.78%, from a closing price of $1.84 per share on August 5, 2026, to $1.20 per share on August 6, 2026.

Click here for more information:

https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit

.

What Can You Do?

If you invested in UWM, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit
 

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/uwm-holdings-class-action-lawsuit
 

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/uwmc-stock-news-uwm-holdings-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-34-stock-drop-302853508.html

SOURCE Bleichmar Fonti & Auld LLP

Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/capricor-class-action-lawsuit.

Key Details of the Capricor Therapeutics ($CAPR) Class Action:

• Lead Plaintiff Deadline: September 28, 2026
• Lawsuit Allegations: Securities fraud alleging Capricor made false statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application.
• Largest Alleged Stock Drop: July 27, 2026 – 64.5% Stock Drop
• Court: U.S. District Court for the Southern District of California
• Action: Contact BFA Law to discuss your rights

Investors have until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Capricor securities. The class action is pending in the U.S. District Court for the Southern District of California. It is captioned Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385.

Why is Capricor Being Sued for Securities Fraud?

Capricor is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an investigational cell therapy being developed for Duchenne muscular dystrophy.

According to the complaint, Capricor submitted a Biologics License Application to the FDA for Deramiocel in late 2024. In July 2025, the FDA issued a Complete Response Letter stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and that additional clinical data was needed.

As alleged, Capricor failed to disclose that it adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel and that the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel BLA.

Why did Capricor’s Stock Drop? 

On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting concerning Deramiocel. The FDA briefing documents reportedly raised concerns about post-hoc changes to Capricor’s statistical analysis plan, including changes to the methodology for calculating the primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded. This news caused the price of Capricor stock to decline $12.70 per share, or 64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per share on July 27, 2026, the following trading day.

On July 29, 2026, the FDA advisory committee met to discuss the Deramiocel BLA. The next day, a medical news website named Medscape reported that in a non-binding 9-3 vote, the panel concluded that available evidence did not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. On this news, Capricor’s stock dropped $2.38 per share, or 36%, from a closing price of $6.57 per share on July 29, 2026, to $4.19 per share on July 30, 2026.

Click here for more information:

https://www.bfalaw.com/cases/capricor-class-action-lawsuit

.

What Can You Do?

If you invested in Capricor Therapeutics securities, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/capricor-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/capricor-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/capr-stock-news-capricor-therapeutics-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-64-stock-drop-302853484.html

SOURCE Bleichmar Fonti & Auld LLP

A securities fraud class action lawsuit has been filed on behalf of Rackspace investors after its stock plummeted 33.6% because Rackspace allegedly misled investors about its AI efforts and their impact on the company’s financial performance.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Rackspace Technology, Inc. (NASDAQ:RXT) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Rackspace, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/rackspace-class-action-lawsuit.

Key Details of the Rackspace ($RXT) Class Action:

• Lead Plaintiff Deadline: September 28, 2026
• 
  Alleged Misconduct: Securities fraud alleging that Rackspace misled investors about its AI efforts and their impact on the company’s financial performance
• Stock Drop: July 9, 2026 – 33.6% Stock Drop
• Court: U.S. District Court for the Southern District of New York
• Action: Contact BFA Law to discuss your rights

Investors have until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Rackspace securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Morgan-Reed v. Rackspace Technology, Inc., No. 26-cv-6491.

Why is Rackspace Being Sued for Securities Fraud?

Rackspace is a hybrid cloud and AI solutions company that operates physical infrastructure to host cloud services and artificial intelligence. The company also provides Rackspace AI, a portfolio of AI services to help organizations scale AI adoption.

During the relevant period, the company announced it signed a memorandum of understanding with Advanced Micro Devices, Inc. (“AMD”) to assist in building out its AI infrastructure and enhance its AI capabilities. That same day, the company reaffirmed its full year revenue guidance.

Rackspace told investors that the “AMD piece really fits into how” the company’s technology stack operates. Rackspace also stated that the AMD partnership “give[s] [the Company] confidence in the full year Private Cloud growth profile.”

As alleged, in truth, the company’s AI efforts would require Rackspace to significantly re-prioritize its capacity and pull capacity away from revenue generating segments.

Why did Rackspace’s Stock Drop?

On July 9, 2026, Rackspace revealed that its AI investments would require a significant re-prioritization of resources and a “transition away” from certain revenue generating segments. As a result, Rackspace revealed it was cutting its full year 2026 revenue guidance by $150 million and its full year Private Cloud revenue outlook by $25 million.

This news caused the price of Rackspace stock to decline $2.21 per share, or 33.6%, from a closing price of $6.58 per share on July 8, 2026, to $4.37 per share on July 9, 2026.

Click here for more information:

https://www.bfalaw.com/cases/rackspace-class-action-lawsuit

.

What Can You Do?

If you invested in Rackspace, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/rackspace-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/rackspace-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rxt-stock-news-rackspace-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-33-stock-drop-302853517.html

SOURCE Bleichmar Fonti & Auld LLP

SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ — Wix.com Ltd. (NASDAQ: WIX) faces a securities class action in the wake of mid-May’s massive 27% drop in the price of the company’s shares after Wix announced its Q1 2026 financial results. Among the disappointments, operating expenses unexpectedly spiked 46% year-over-year leading to questions about the company’s ability to defend its core business.

The case is Yappi v. Wix.com Ltd., et al., No. 26-cv-08852 (N.D. Ill.).

The lawsuit seeks to represent investors who purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026.

National shareholders rights firm Hagens Berman continues its investigation into claims that Wix violated the federal securities laws and urges Wix investors who suffered significant losses to contact the firm now to discuss their rights.

Class Period: Feb. 19, 2025 – May 12, 2026
Lead Plaintiff Deadline: Sept. 22, 2026
Visit: www.hbsslaw.com/investor-fraud/wix
Contact the Firm Now: [email protected]
                                        844-916-0895

Wix.com Ltd. (WIX) Securities Class Action:

Global web development platform company Wix faces increasing competitive challenges posed by vibe coding, a software development trend where a person builds apps or websites by giving plain-language instructions to an AI rather than writing code line-by-line.

To confront this challenge, Wix positioned AI initiatives, Base44 and Harmony, as its two-pillar response to the vibe coding trend threatening the company’s core business.

The company has provided numerous assurances to investors, including that “[w]e expect innovation-driven growth to be accompanied by high impact but disciplined investments to fully unlock the market opportunity ahead for both Wix and Base44.” In addition, Wix has emphasized “[e]arly Wix Harmony performance is better than expected, with improved conversion and monetization[,]” and “[t]ogether, Wix Harmony and Base44 open up the world of what’s possible on Wix[.]”

The complaint alleges that Wix made false and misleading statements while failing to disclose that, with respect to its AI product offerings, Wix overstated their competitiveness and performance, understated the costs associated with developing and promoting them and, accordingly, overstated their commercial and financial benefits.

Investors began to learn the truth on May 21, 2025, when Wix provided 2025 revenue guidance falling short of analyst expectation and fueling concerns about the company’s competitiveness. Then, on November 19, 2025, Wix reported its Q3 2025 results indicating rising post-Base44-acquisition costs (AI compute and marketing) were having a material negative impact on its financial results. Each of these triggered sharp selloffs in the price of the stock and triggered analyst downgrades on concerns over core business growth deceleration, increasing costs, and competitive positioning.

Finally, on May 13, 2026, Wix revealed aggressive and front-loaded AI compute expenses for Harmony and Base44. More specifically, the rapid expansion of Base44 and Harmony rollout radically altered Wix’s cost structure primarily through front-loading sales and marketing (“S&M”) expenses. Collectively, the initiatives drove non-GAAP S&M expenses to $190.7 million, a year-over-year 88% increase that caused the company’s non-GAAP operating margin to collapse from 21% during the prior year period to just 5% while sending its quarterly operating expenses up 46% from the prior year period.

During the earnings call that day, management acknowledged that professional development customers were using competing AI tools, the Harmony platform had “holes” and “missing capabilities,” and there had been delays in delivering product updates and innovation to professional developer customers resulting in Wix falling behind their workflows and needs.

The market swiftly reacted that day, scalping over $1.1 billion from Wix’s market capitalization and prompting analysts’ surprise over the magnitude of the margin miss.

“We’re investigating whether Wix may have intentionally understated the adverse effects of its AI initiatives on its operating results,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Wix and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Wix case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Wix should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wix-investor-alert-wixcom-ltd-investors-with-substantial-losses-have-opportunity-to-lead-the-wix-class-action-lawsuit-302853602.html

SOURCE Hagens Berman Sobol Shapiro LLP

A securities fraud class action lawsuit has been filed on behalf of Peabody investors after its stock plummeted over 9% because Peabody allegedly misled investors regarding the coal production at Centurion, its flagship premium hard coking coal mine.

NEW YORK, Aug. 18, 2026 /PRNewswire/ — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Peabody Energy Corporation (NYSE:BTU) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Peabody, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/peabody-class-action-lawsuit.

Key Details of the Peabody ($BTU) Class Action:

• Lead Plaintiff Deadline: August 24, 2026
• 
  Alleged Misconduct: Securities fraud relating to Peabody’s statements about the coal production at Centurion, its flagship premium hard coking coal mine.
• Largest Alleged Stock Drop: March 30, 2026 – 9.7% stock drop
• Court: U.S. District Court for the Eastern District of Missouri
• Action: Contact BFA Law to discuss your rights

Investors have until August 24, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Peabody common stock. The class action is pending in the U.S. District Court for the Eastern District of Missouri. It is captioned McGeachy v. Peabody, et al., No. 26-cv-01020.

Why is Peabody Being Sued for Securities Fraud?

Peabody is a producer of metallurgic and thermal coal that owns interests in 16 active coal mining operations in the United States and Australia.

According to the complaint, during the relevant period, Peabody announced it would be increasing production from its flagship premium hard coking coal mine, Centurion due to an acceleration of longwall operations. Peabody stated that shipments of Centurion’s premium hard coking coal would expand sevenfold in 2026 to 3.5 million tons and even more beyond that time. On February 5, 2026, Peabody indicated that the team was “putting the finishing touches on the Centurion mine in advance of starting longwall mining, well ahead of its original schedule.”

As alleged, in truth, the Centurion mine was facing significant commissioning challenges resulting in increased costs and volume decreases in its production.

Why did Peabody’s Stock Drop?

On March 30, 2026, Peabody announced lower sales volume from the Centurion mine due to a delivery of only 250,000 tons in the first quarter. Peabody attributed the low volume to “greater than anticipated mine commissioning challenges.”

This news caused the price of Peabody common stock to drop $3.82 per share, or 9.7%, from $39.50 per share on March 27, 2026, to $35.68 per share on March 30, 2026.

Then, on May 5, 2026, Peabody announced additional delays to the commissioning of the Centurion mine as well as increased costs and lower volume. Peabody stated it only expected to sell about 300,000 tons in the second quarter and reduced its full year sales outlook for Centurion from 3.5 million tons to 2.5 million tons.

This news caused the price of Peabody common stock to drop $1.52 per share, or 5.7%, from $26.52 per share on May 4, 2026, to $25.00 per share on May 5, 2025.

Click here for more information:

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

.

What Can You Do?

If you invested in Peabody, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.”  One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/btu-stock-news-peabody-sued-for-securities-fraud-over-alleged-misrepresentations-and-corresponding-10-stock-drop-302853469.html

SOURCE Bleichmar Fonti & Auld LLP